https://www.selleckchem.com/pr....oducts/crenolanib-cp
oscopy. Postoperative complications occurred in 8 patients (42.1%); none were of grade IV or V. Median follow-up was 66 months (range 3-312). The majority of patients (n=15, 78.9%) were disease free with surgery alone. None received adjuvant mitotane therapy (AMT). Four patients (21%) experienced metachronous metastases and 3 (15.8%) local recurrence after a median time of 10.5 months (range 2-6 and 9.3 months (range 1.5-3, respectively. The 5-year overall survival rate was 47.4%. CONCLUSIONS Our findings confirm both t
Like
Comment
Share
